secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001193125-26-165297
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca narrows ERAS-0015 Phase 1 data readout timeline to mid-May 2026
----------------------------------------------------------------------

- Narrowed Phase 1 monotherapy data readout for pan-RAS molecular glue ERAS-0015 to no later than mid-May 2026 (prior: first half 2026).
- Data from two trials: Erasca's AURORAS-1 (RAS-mutant solid tumors) and Joyo's JYP0015M101 (China, specific RAS mutations).
- No financial or regulatory update; no safety or efficacy data disclosed yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/0001193125-26-165297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/eras-20260421.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-165297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer